Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Acquires 12,000 Shares of Stock

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd bought 12,000 shares of Vigil Neuroscience stock in a transaction that occurred on Thursday, December 19th. The stock was bought at an average cost of $1.71 per share, for a total transaction of $20,520.00. Following the purchase, the director now owns 12,000 shares in the company, valued at $20,520. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Vigil Neuroscience Price Performance

Shares of VIGL opened at $1.66 on Friday. The company has a 50-day moving average of $3.05 and a two-hundred day moving average of $3.50. Vigil Neuroscience, Inc. has a one year low of $1.60 and a one year high of $6.06. The stock has a market cap of $67.86 million, a price-to-earnings ratio of -0.81 and a beta of 1.65.

Wall Street Analysts Forecast Growth

VIGL has been the subject of several recent analyst reports. Wedbush lifted their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, November 8th. William Blair started coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating for the company. JMP Securities restated a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research note on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vigil Neuroscience has an average rating of “Buy” and an average target price of $19.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new stake in shares of Vigil Neuroscience in the second quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Vigil Neuroscience during the second quarter worth $87,000. Renaissance Technologies LLC grew its position in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares in the last quarter. Walleye Capital LLC raised its stake in shares of Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in shares of Vigil Neuroscience in the 3rd quarter valued at $442,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.